Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Glycerol Phenylbutyrate
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Children's Hospital Colorado | SLC6A1 Connect | STXBP1 Foundation | Clara Inspired | University of Pennsylvania Orphan Disease Center | Horizon Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 23, 2021
Lead Product(s) : Glycerol Phenylbutyrate
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Children's Hospital Colorado | SLC6A1 Connect | STXBP1 Foundation | Clara Inspired | University of Pennsylvania Orphan Disease Center | Horizon Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glycerol Phenylbutyrate
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 07, 2017
Lead Product(s) : Glycerol Phenylbutyrate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glycerol Phenylbutyrate
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : University of Alabama at Birmingham | Children's Hospital of Philadelphia | Johns Hopkins University | Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 23, 2014
Lead Product(s) : Glycerol Phenylbutyrate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : University of Alabama at Birmingham | Children's Hospital of Philadelphia | Johns Hopkins University | Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glycerol Phenylbutyrate
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 22, 2014
Lead Product(s) : Glycerol Phenylbutyrate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glycerol Phenylbutyrate
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Use of Ravictiâ„¢ in Patients With MCAD Deficiency With the 985A>G (K304E) Mutation
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 20, 2013
Lead Product(s) : Glycerol Phenylbutyrate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glycerol Phenylbutyrate
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 04, 2011
Lead Product(s) : Glycerol Phenylbutyrate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glycerol Phenylbutyrate
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 10, 2010
Lead Product(s) : Glycerol Phenylbutyrate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glycerol Phenylbutyrate
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 03, 2010
Lead Product(s) : Glycerol Phenylbutyrate
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable